-
1.发明申请Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof 失效具有向异性作用的化合物，它们的前药，含有它们的药物组合物及其用途公开(公告)号：US20090163565A1
公开(公告)日：2009-06-25
申请号：US12378475
申请日：2009-02-13
IPC分类号： A61K31/4166 , C07D235/02 , A61P25/28
CPC分类号： C07D487/04
摘要： Described herein are new bicyclic arylimidazolones having nootropic action (i.e., protecting and stimulating cerebral functions), analgesic action and anti hyperalgesic action; also described is the process for their preparation and pharmaceutical compositions comprising them, useful for the treatment of cognitive deficits, and of various types of pain.
摘要翻译： 本文描述了具有向异性作用（即保护和刺激脑功能），止痛作用和抗痛觉过敏作用的新型双环芳基咪唑酮; 还描述了其制备方法和包含它们的药物组合物，其可用于治疗认知缺陷和各种类型的疼痛。
-
2.发明申请3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS 审中-公开3-取代的喹啉-4-羧酰胺衍生物作为NK-3和NK-2受体拮抗剂公开(公告)号：US20070259882A1
公开(公告)日：2007-11-08
申请号：US11768338
申请日：2007-06-26
IPC分类号： A61K31/497 , A61P25/00 , C07D401/00
CPC分类号： C07D215/50 , C07D215/16 , C07D215/52 , C07D401/04 , C07D401/06 , C07D401/14 , C07D409/04 , C07D409/14 , C07D417/06 , C07D487/04
摘要： A compound of formula (I) below or a pharmaceutically acceptable salt or solvate thereof:
摘要翻译： 下式（I）的化合物或其药学上可接受的盐或溶剂合物：
-
3.发明申请3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists 审中-公开3-取代的喹啉-4-羧酰胺衍生物作为NK-3和NK-2受体拮抗剂公开(公告)号：US20060229315A1
公开(公告)日：2006-10-12
申请号：US11426956
申请日：2006-06-28
IPC分类号： A61K31/496 , C07D403/02
CPC分类号： C07D215/50 , C07D215/16 , C07D215/52 , C07D401/04 , C07D401/06 , C07D401/14 , C07D409/04 , C07D409/14 , C07D417/06 , C07D487/04
摘要： A compound of formula (I) below or a pharmaceutically acceptable salt or solvate thereof:
摘要翻译： 下式（I）的化合物或其药学上可接受的盐或溶剂合物：
-
公开(公告)号：US20110251250A1
公开(公告)日：2011-10-13
申请号：US13166088
申请日：2011-06-22
申请人： Carlo FARINA , Carla Ghelardini , Paola Petrillo
发明人： Carlo FARINA , Carla Ghelardini , Paola Petrillo
IPC分类号： A61K31/4188 , A61P25/04 , A61P19/02
CPC分类号： A61K31/7068 , A61K31/4188 , A61K31/555 , A61K45/06 , A61K2300/00
摘要： The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.
摘要翻译： 公开了使用二拉西坦治疗慢性疼痛。 在比以前公开的与其认知增强活性（即改善学习和记忆）相比更高的剂量下，双拉西坦能够完全恢复与慢性疼痛的几种动物模型相关的痛觉过敏或异常性疼痛。 二西拉西坦在与抗病毒和化疗药物治疗相关的医源性神经病变以及由骨关节炎引起的疼痛状况下表现出高活性。 此外，即使在比最高治疗剂量高10倍的剂量下，二西拉坦也没有毒性。 因此公开了用高效和基本上无毒化合物治疗这种衰弱病态的可能性。
-
-
-
搜索结果
4 条记录 (耗时 0.021 秒)
